Plain-English translation of NCT05664191 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This completed trial examined whether a medication called levosimendag could help protect the heart and brain after a ruptured brain aneurysm (a type of sudden stroke). Patients hospitalized for this condition received either the medication or a placebo, and researchers studied whether this treatment could reduce the chance of dangerous complications like heart problems or reduced blood flow to the brain.
After a ruptured brain aneurysm, patients often develop serious complications that can damage the heart and brain further. Currently, there is no proven way to prevent these complications, so researchers wanted to test whether this medication could help protect patients during their recovery.
Participants who enrolled received either the experimental medication or a placebo given through an IV infusion on two separate days (day 1 and day 8 after enrollment). The infusion lasted 24 hours each time. Researchers then monitored participants closely over the following two weeks to see whether they developed any of the serious complications the trial was designed to prevent, such as heart dysfunction or reduced blood flow to the brain.
AI-generated summary from trial data · Sep 17, 2026 · Not medical advice
France
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Orion Corporation, Orion Pharma
Enrollment target
~30 participants
Started
October 2023
Primary completion
April 2026
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in August 2026.